Neogenomics (NASDAQ: NEO) reported Q4 EPS of $0.00, $0.01 better than the analyst estimate of ($0.01). Revenue for the quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings Guidance